Background: Children found to be anemic on routine screening by HemoCue, a
rapid and relatively inexpensive method of screening for hemoglobin (Hb), a
re often prescribed iron as a diagnostic tool and potential treatment for p
resumed iron deficiency anemia (IDA). We questioned this approach given the
declining prevalence of IDA and the concomitant relative increase in other
causes of anemia.
Objective: To evaluate the practice of Hb screening for IDA by determining
the prevalence of anemia by HemoCue; the proportion of anemic patients trea
ted with iron and followed up; the frequency of repeated Hb testing, additi
onal iron studies, and iron prescriptions; and the 6-month outcomes of trea
ted and untreated anemia.
Design: Retrospective cohort study.
Results: Of 1358 children aged 9 to 36 months who underwent screening, 343
(25%) had anemia, defined as a Hb level of less than 110 gn. Outpatient med
ical records of 334 of the anemic children revealed that 239 (72%) were pre
scribed iron while 95 (28%) were not prescribed iron at the first visit for
anemia. Anemia follow-up rates were low for the prescribed and not prescri
bed groups: 7% vs 5% returned within 1 month while 37% vs 42% did not retur
n within 6 months for follow-up. Of the children who were prescribed iron,
107 (71%) of 150 responded to treatment or anemia resolved within 6 months
compared with 27 (68%) of 40 not prescribed iron. Children underwent repeat
ed blood testing for measurement of Hb and complete blood cell count, but u
nderwent few iron-specific studies.
Conclusions: Routine screening for IDA by HemaCue followed by a therapeutic
trial of iron was problematic because of a high rate of anemia in this pre
dominantly African American population, low follow-up rates, and a high spo
ntaneous resolution rate. Prospective studies are needed to evaluate other
screening methods to differentiate IDA from other forms of anemia and to im
prove compliance and outcome in inner-city children.